Stablix Therapeutics has launched with $63m in equity financing to commercialise research pioneered in Henry Colecraft’s laboratory at Columbia University.
Stablix Therapeutics, a US-based biotechnology company advancing research from Columbia University, launched yesterday with $63m in series A funding led by Versant Ventures.
The round also included Alexandria Venture Investments, the investment arm of life science real estate investment trust Alexandria Real Estate Equities, as well as New Enterprise Associates (NEA), Cormorant Capital and Euclidean Capital.
Stablix has developed targeted protein stabilisation technology that has applications in the treatment of rare diseases, cancer and immunological disorders.
The platform builds on work by Henry Colecraft, the John C Dalton professor of physiology and cellular biophysics at Columbia University. Colecraft’s co-founders include former PhD candidate Scott Kanner.
Carlo Rizzuto, partner at Versant and acting chief executive of Stablix, said: “Stablix possesses a first-in-category platform that can restore protein stability and function in a target-selective manner.
“We are very pleased to launch this company to address this important…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
